THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, a bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in **Everest Medicines Limited**, you should at once hand this circular, together with the enclosed form of proxy, to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

EVEREST MEDICINES
云 顶 新 耀

Everest Medicines Limited
雲頂新耀有限公司
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 1952)

(1) PROPOSED RE-ELECTION OF DIRECTORS; (2) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES; (3) PROPOSED RE-APPOINTMENT OF RETIRING AUDITOR; AND (4) NOTICE OF ANNUAL GENERAL MEETING

Unless the context otherwise requires, all capitalized terms used in this cover page shall have the same meanings as those defined in the section headed "Definitions" of this circular.

The notice convening the AGM to be held on Friday, 26 June 2026 at 9:30 a.m. is set out in this circular.

The AGM will be held by way of virtual meeting using an electronic system which allows all Shareholders to participate and vote through the Online Platform. Whether or not Shareholders are able to attend the AGM, they are encouraged to appoint the Chairman of the AGM as their proxy. The deadline to submit completed proxy forms is Wednesday, 24 June 2026 at 9:30 a.m.

SUMMARY OF GUIDANCE FOR THE AGM

Please see pages 1 to 3 of this circular for details of the guidance for the virtual AGM, including:

- Attendance
  - Online Platform
  - Login details for registered Shareholders
  - Login details for non-registered Shareholders
  - Login details for duly appointed proxies or corporate representatives
  - Login details for new registered Shareholders
  - Proxy appointment and voting
- Questions at or prior to the AGM

This circular, together with the form of proxy, are also published on the websites of the Stock Exchange (http://www.hkexnews.hk) and the Company (www.everestmedicines.com).

Hong Kong, 3 June 2026

CONTENTS

Page

Guidance for the AGM 1

Definitions 4

Letter from the Board

1. Introduction 7
2. Proposed Re-election of Directors 8
3. Proposed Granting of General Mandate to Repurchase Shares 8
4. Proposed Granting of General Mandate to Issue Shares 9
5. Proposed Re-Appointment of Retiring Auditor 9
6. AGM and Proxy Arrangement 9
7. Recommendation 10

Appendix I — Details of the Directors Proposed to be Re-elected at the AGM ... 11

Appendix II — Explanatory Statement on the Share Repurchase Mandate 17

Notice of Annual General Meeting 20

The forthcoming AGM of the Company will be held by way of virtual meeting through broadcasting at the website https://meetings.computershare.com/everestmed_2026AGM (the "**Online Platform**"). Shareholders attending and participating in the AGM using the Online Platform will be deemed present at, and will be counted towards the quorum of, the AGM and they will be able to cast their votes and submit questions through the Online Platform. Unless otherwise defined herein, terms used in this Guidance for the AGM shall have the same meanings in the "Definitions" section on pages 4 to 6.

ATTENDANCE

Both registered and non-registered Shareholders will be able to **attend and view** a live webcast of the AGM, **raise questions** and **cast vote** through the Online Platform.

Online Platform

The Online Platform will be opened for registered and non-registered Shareholders to log into approximately 30 minutes prior to the commencement of the AGM and can be accessed from any location with internet connection by a smart phone, tablet device or computer. Shareholders should allow ample time to check into the Online Platform to complete the related procedures.

A step-by-step "Online Meeting User Guide" for the login process of the AGM has been made available on the Company's website at www.everestmedicines.com for assistance.

Login details for registered Shareholders

For registered Shareholders, the login details for joining the AGM through the Online Platform are provided in the notification letter that has been sent together with this circular.

Login details for non-registered Shareholders

Non-registered Shareholders who wish to attend and vote at the AGM through the Online Platform should:

(1) contact and instruct your banks, brokers, custodians, nominees or HKSCC Nominees Limited by which your Shares are held (collectively, the "**Intermediary**") to appoint you as the proxies or corporate representatives to attend and vote at the AGM; and

(2) provide your email address(es) to your Intermediary before the deadline imposed by your Intermediary.

Login details to access the Online Platform will be sent to the non-registered Shareholders by the Company's share registrar, Computershare Hong Kong Investor Services Limited ("**Computershare**"), to the email address(es) you provided to the Intermediary. Any non registered Shareholder who has provided an email address through the relevant Intermediary for this purpose but has not received the login details by email by 9:30 a.m. on Thursday, 25 June 2026 should reach out to Computershare for assistance.

Without the login details, non-registered Shareholders will not be able to attend, participate or vote at the AGM. Non-registered Shareholders should therefore give clear and specific instructions to their Intermediary in respect of both (1) and (2) above.

Login details for duly appointed proxies or corporate representatives

Login details to access the Online Platform will be sent by Computershare to the email address(es) of the proxies provided in the returned forms of proxy.

For corporate Shareholders who wish to appoint representatives to attend, participate and vote at the AGM on their behalf through the Online Platform, please call the service hotline of Computershare at (852) 2862 8555 during business hours from 9:00 a.m. to 6:00 p.m. (Hong Kong time) from Monday to Friday, excluding Hong Kong public holidays for arrangements.

Any proxy or corporate representative who has not received the login details by email by 9:30 a.m. on Thursday, 25 June 2026 should reach out to Computershare for assistance.

Login details for new registered Shareholders

For new registered Shareholders (who registered after the dispatch date of the AGM documents but are still entitled to attend, participate and vote at the AGM), login details can be obtained by request from Computershare with the contact details below:

Computershare Hong Kong Investor Services Limited
17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong
Tel: (852) 2862 8555
Fax: (852) 2865 0990
Website: www.computershare.com/hk/contact

POINTS TO NOTE

Registered and non-registered Shareholders should note that only one device is allowed in respect of each set of login details. Please also keep the login details in safe custody for use at the AGM and do not disclose them to anyone else. Neither the Company nor its agents assume any obligation or liability whatsoever in connection with the transmission of the login details or any use of the login details for voting or otherwise. Shareholders should also note that an active and stable internet connection is required in order to allow them to participate, vote and submit questions at the AGM through the Online Platform. It is the users' own responsibility to ensure that they have a sufficient and stable internet connection.

PROXY APPOINTMENT AND VOTING

Voting by Proxy

A Shareholder who is entitled to attend and vote at the AGM is entitled to appoint a proxy to exercise the Shareholder's rights at the AGM. A proxy may attend, speak and vote instead of the Shareholder who needs not be a Shareholder of the Company.

Irrespective of whether Shareholders are able to attend the AGM, you are encouraged to appoint the Chairman of the AGM as your proxy. **If the proxy appointed is not the Chairman of the AGM, you are requested to provide a valid email address of your proxy to receive the login details. If no email address is provided, your proxy cannot attend, participate or vote at the AGM.**

Where there are joint registered holders of any Share(s), any one of such persons (or his/her proxy) may vote at the AGM, through the Online Platform, in respect of such Share(s) as if he/she is solely entitled to, but if more than one of such joint holders (or his/her proxy) is present at the AGM through the Online Platform that **only one device** is allowed per login.

Proxy Forms and Voting Record Date

A proxy form is enclosed with this circular or can be downloaded from the website of the Stock Exchange at www.hkexnews.hk and on the Company's website at www.everestmedicines.com.

All proxy forms must be completed and signed in accordance with the instructions printed thereon and be returned to Computershare at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not less than 48 hours before the time appointed for the holding of the AGM or any adjournment thereof (as the case may be). **The deadline to submit completed proxy forms is Wednesday, 24 June 2026 at 9:30 a.m.**

Submission of the form of proxy will not preclude any member of the Company from attending the AGM through the Online Platform or any adjournment thereof and voting online if such member so wishes and in such event, the form of proxy will be deemed to be revoked.

The record date for determining the Shareholders' eligibility for attending and voting at the AGM is Friday, 26 June 2026.

QUESTIONS AT OR PRIOR TO THE AGM

Shareholders attending the AGM online will be able to raise questions relevant to the proposed resolutions using the Online Platform. The Q&A time will be restricted to a maximum of 15 minutes.

Prior to the AGM, irrespective of whether Shareholders attend the AGM or not, they are also welcome to send any questions in writing about any resolution or about the Company, or have any matter for communication with the Board, to the Company's registered office or email at IR@everestmedicines.com no later than 6:00 p.m. on Wednesday, 24 June 2026.

The Company will endeavor to address relevant questions in relation to the proposed resolutions at the AGM. However, the Company may not be able to answer all the questions during the time allocated. Unanswered questions may be responded to after the AGM.

If Shareholders have any questions relating to the AGM arrangements, please contact the share registrar of the Company as follows:

Computershare Hong Kong Investor Services Limited
17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong
Tel: (852) 2862 8555
Fax: (852) 2865 0990
Online Enquiries: www.computershare.com/hk/en/online_feedback

In this circular, unless the context otherwise requires, the following expressions shall have the following meanings:

"AGM" or "Annual General Meeting"	the annual general meeting of the Company to be held on Friday, 26 June 2026 at 9:30 a.m., to consider and, if appropriate, to approve the resolutions contained in the notice of the meeting which is set out on pages 20 to 24 of this circular, or any adjournment thereof
"Articles" or "Articles of Association"	the eighth amended and restated articles of association of the Company, currently in force
"associate"	has the meaning ascribed to it under the Listing Rules
"Board"	the board of Directors
"CBC Group"	mainly comprises C-Bridge Healthcare Fund II, L.P., C-Bridge Investment Everest Limited, C-Bridge II Investment Eight Limited, C-Bridge Healthcare Fund IV, L.P., C-Bridge IV Investment Two Limited, C Bridge IV Investment Nine Limited Ltd., C-Bridge Capital Investment Management, Ltd., CBC Group Investment Management, Ltd, C-Bridge Value Creation Limited and Everest Management Holding Co., Ltd
"CCASS"	Central Clearing and Settlement System, a securities settlement system used within the Hong Kong Exchanges and Clearing Limited market system
"Company"	Everest Medicines Limited, an exempted company incorporated in the Cayman Islands with limited liability, the Shares of which are listed on the Main Board of the Stock Exchange (stock code: 1952)
"connected person(s)"	has the meaning ascribed to it under the Listing Rules
"Director(s)"	the director(s) of the Company
"HK$"	Hong Kong dollars, the lawful currency of Hong Kong
"HKSCC"	Hong Kong Securities Clearing Company Limited, a wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited
"Hong Kong"	the Hong Kong Special Administrative Region of the People's Republic of China

"Latest Practicable Date"	28 May 2026, being the latest practicable date prior to the printing of this circular for ascertaining certain information in this circular
"Listing Date"	9 October 2020
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange as amended from time to time
"Memorandum and Articles of Association"	the eighth amended and restated memorandum and articles of association of the Company currently in force
"Nomination Committee"	the nomination committee of the Company
"Online Platform"	the internet based platform (http://meetings.computershare.com/everestmed_2026AGM) through which Shareholders can attend, participate and vote by electronic means at the AGM
"Remuneration Committee"	the remuneration committee of the Company
"Repurchase Mandate"	a general mandate proposed to be granted to the Directors to repurchase Shares on the Stock Exchange of not exceeding 10% of the total number of issued shares of the Company (excluding any treasury Shares) as at the date of passing of the proposed ordinary resolution contained in item 4 of the notice of the Annual General Meeting
"RMB"	Renminbi, the lawful currency of the People's Republic of China
"Sale Mandate"	a general mandate proposed to be granted to the Directors to allot, issue or deal with additional Shares (including any sale and transfer of Shares out of treasury that are held as treasury Shares) of not exceeding 20% of the total number of issued shares of the Company as at the date of passing of the proposed ordinary resolution contained in item 5 of the notice of the Annual General Meeting
"SFO"	Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended from time to time
"Share(s)"	ordinary share(s) of US$0.0001 each in the issued capital of the Company or if there has been a subsequent sub-division, consolidation, reclassification or reconstruction of the share capital of the Company, shares forming part of the ordinary equity share capital of the Company

"Shareholder(s)"	holder(s) of Share(s)
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Takeovers Code"	The Code on Takeovers and Mergers approved by the Securities and Futures Commission as amended from time to time
"treasury Shares"	has the meaning ascribed to it under the Listing Rules
"US$" or "USD"	United States dollars, the lawful currency of the United States of America
"%"	percent

References to time and dates in this circular are to Hong Kong time and dates.

In the event of any inconsistency, the English version shall prevail over the Chinese version.



Everest Medicines Limited
雲頂新耀有限公司
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 1952)

Executive Directors:
Mr. Yifang Wu *(Chairman)*
Mr. Yongqing Luo *(Chief executive officer)*
Mr. Ian Ying Woo
(President, Chief financial officer)

Non-executive Directors:
Mr. Wei Fu
Mr. William Ki Chul Cho
Mr. Xin Sun

Independent Non-executive Directors:
Ms. Hoi Yam Chui
Mr. Yifan Li
Mr. Shidong Jiang

Registered Office:
PO Box 309
Ugland House
Grand Cayman KY1–1104
Cayman Islands

Head Office:
17/F., AIA Financial Center
866 East Changzhi Road, Hongkou District
Shanghai 200082, China

Principal Place of Business in Hong Kong:
Room 1912, 19/F, Lee Garden One
33 Hysan Avenue
Causeway Bay, Hong Kong

3 June 2026

To the Shareholders

Dear Sir/Madam,

(1) PROPOSED RE-ELECTION OF DIRECTORS; (2) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES; (3) PROPOSED RE-APPOINTMENT OF RETIRING AUDITOR; AND (4) NOTICE OF ANNUAL GENERAL MEETING

1. INTRODUCTION

The purpose of this circular is to provide the Shareholders with information in respect of certain resolutions to be proposed at the AGM to be held on Friday, 26 June 2026.

2. PROPOSED RE-ELECTION OF DIRECTORS

In accordance with Article 16.19 of the Articles of Association, Mr. Wei Fu, Mr. William Ki Chul Cho and Ms. Hoi Yam Chui shall retire at the AGM. In addition, Mr. Yifang Wu and Mr. Xin Sun who were appointed by the Board on 10 October 2025 and 11 December 2025 respectively, shall hold office until the AGM pursuant to Article 16.2 of the Company's Memorandum and Articles of Association. All of the above Directors, being eligible, will offer themselves for re-election at the AGM.

Ms. Hoi Yam Chui, the retiring independent non-executive Director, has confirmed her independence with reference to the factors set out in Rule 3.13 of the Listing Rules. The Board has reviewed its structure and composition, the independence confirmation given by Ms. Hoi Yam Chui, the professional qualifications, skills and experience (further details are of which are set out in Appendix I to the circular), time commitment and contribution of Ms. Hoi Yam Chiu with reference to the nomination principles and criteria set out in the Company's board diversity policy and director nomination policy. The Nomination Committee has recommended to the Board on the re-election Ms. Hoi Yam Chui at the AGM. The Board considers that Ms. Hoi Yam Chui is independent according to the independence guidelines set out in the Listing Rules. After due consideration of the contribution of Ms. Hoi Yam Chui to the Company, the Board is satisfied that Ms. Hoi Yam Chui will continue to bring valuable business experience, knowledge and professionalism to the Board for its efficient and effective functioning and diversity.

The Board is of the view that with the extensive knowledge and invaluable experience of Ms. Hoi Yam Chui in pharmaceutical industry, she will contribute to the diversity of the Board and provide new thoughts for the Company's overall strategic planning and business development. The Board also believes that the appointment of Ms. Hoi Yam Chui is in the best interests of the Company and the Shareholders as a whole.

Details of the Directors proposed for re-election at the AGM are set out in Appendix I to this circular.

3. PROPOSED GRANTING OF GENERAL MANDATE TO REPURCHASE SHARES

On 27 June 2025, a resolution was passed by the Shareholders to grant a general mandate to the Directors to repurchase Shares. Such mandate will lapse at the conclusion of the AGM. In order to give the Company the flexibility to repurchase Shares if and when appropriate, an ordinary resolution will be proposed at the AGM to approve the granting of the Repurchase Mandate to the Directors to repurchase Shares on the Stock Exchange of not exceeding 10% of the total number of issued Shares of the Company (excluding any treasury Shares) as at the date of passing of the proposed ordinary resolution contained in item 4 of the notice of the AGM (i.e. a total of 35,379,997 Shares on the basis that no further Shares are issued or repurchased before the AGM).

An explanatory statement required by the Listing Rules to provide the Shareholders with requisite information reasonably necessary for them to make an informed decision on whether to vote for or against the granting of the Repurchase Mandate is set out in Appendix II to this circular.

4. PROPOSED GRANTING OF GENERAL MANDATE TO ISSUE SHARES

On 27 June 2025, a resolution was passed by the then Shareholders to grant a general mandate to the Directors to issue Shares. Such mandate will lapse at the conclusion of the AGM. In order to give the Company the flexibility to issue Shares (including any sale or transfer of treasury Shares) if and when appropriate, an ordinary resolution will be proposed at the AGM to approve the granting of the Sale Mandate to the Directors to allot, issue or deal with additional Shares (including any sale or transfer of treasury Shares) of not exceeding 20% of the total number of issued Shares of the Company (excluding any treasury Shares) as at the date of passing of the proposed ordinary resolution contained in item 5 of the notice of the AGM (i.e. a total of 70,759,995 Shares on the basis that no further Shares are issued or repurchased before the AGM). An ordinary resolution to extend the Sale Mandate by adding the number of Shares repurchased by the Company pursuant to the Repurchase Mandate will also be proposed at the AGM.

5. PROPOSED RE-APPOINTMENT OF RETIRING AUDITOR

The Board proposes to re-appoint Ernst & Young as the auditor of the Company effective until the conclusion of the next annual general meeting of the Company subject to the approval of the Shareholders at the AGM. The Board also proposes and recommends to the Shareholders to authorize the Board at the AGM to fix the remuneration of Ernst & Young as the auditor of the Company.

The estimated remuneration of Ernst & Young for the year 2026, agreed with the auditor and determined based on the Company's business scale and complexity, expected audit scope and timeline, and required resources and professional expertise, is in a range of RMB3,500,000 to RMB3,700,000.

6. AGM AND PROXY ARRANGEMENT

The notice of the AGM is set out on pages 20 to 24 of this circular.

Pursuant to the Listing Rules and the Memorandum and Articles of Association, any vote of Shareholders at a general meeting must be taken by poll except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands. Treasury shares, if any and registered under the name of the Company, shall have no voting rights at the Company's general meetings. For the avoidance of doubt and for the purpose of the Listing Rules, holders of treasury Shares (if any) shall abstain from voting on matters that require shareholders' approval at the Company's general meetings. An announcement on the poll results will be published by the Company after the AGM in the manner prescribed under the Listing Rules.

A form of proxy for use at the AGM is enclosed with this circular and such form of proxy is also published on the websites of the Stock Exchange (http://www.hkexnews.hk) and the Company (www.everestmedicines.com). To be valid, the form of proxy, together with the power of attorney or other authority, if any, under which it is signed, or a notarially certified

copy of that power or authority must be deposited at Computershare at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not less than 48 hours before the time assigned for holding the AGM or any adjournment thereof (as the case may be).

For the AGM to be convened on Friday, 26 June 2026 at 9:30 a.m., the deadline to submit completed proxy forms is Wednesday, 24 June 2026 at 9:30 a.m. Completion and return of the form of proxy will not preclude any member of the Company from attending and voting at the AGM through the Online Platform or any adjournment or postponement thereof, if such member so wishes and in such event, the form of proxy will be deemed to be revoked.

Shareholders are advised to read the "Guidance for the AGM" carefully prior to attending the AGM.

7. RECOMMENDATION

The Directors (including the independent non-executive Directors) consider that the proposed re-election of retiring Directors, the proposed granting of the Repurchase Mandate, the proposed Sale Mandate, and the proposed re-appointment of auditor are in the best interests of the Company and the Shareholders. Accordingly, the Directors recommend the Shareholders to vote in favour of the relevant resolutions to be proposed at the AGM.

Yours faithfully,
By Order of the Board
Everest Medicines Limited
Yifang Wu
Chairman and Executive Director

The following are details of the Directors who will retire and being eligible, offer themselves for re-election at the Annual General Meeting.

(1) Mr. Yifang Wu (吳以芳), aged 56, was appointed as an executive Director, chairman of the Board, chairperson of the Nomination Committee and member of the Remuneration Committee on 10 October 2025. Mr. Wu has more than 35 years of experience in the biopharmaceutical industry Mr. Wu will be responsible for leading the Board in setting the Company's strategic direction, providing guidance to the senior management, and overseeing key initiatives in strategic transactions, R&D strategy, and stakeholder engagement. He is currently an Executive Operating Partner of CBC Group, a substantial shareholder of the Company. He has also been a non-executive director of Sisram Medical Ltd (Stock Exchange stock code:1696) since October 2016.

Prior to joining the Group, Mr. Wu worked at Fosun Pharma Group from April 2004 to September 2025 and successively held various positions, including senior vice president, chief operating officer, president, and chief executive officer of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥(集團)股份有限公司) ("**Fosun Pharma**") (Stock Exchange stock code: 2196 and Shanghai Stock Exchange stock code: 600196.SH). Mr. Wu was an executive director of Fosun Pharma from August 2016 to April 2025 and the chairman of the board of Fosun Pharma from October 2020 to April 2025. He was re-designated as a non-executive director of Fosun Pharma from April 2025 to September 2025. In addition, he was also a non-executive director of Shanghai Henlius Biotech, Inc.* (上海複宏漢霖生物技術股份有限公司) (Stock Exchange stock code: 2696) from June 2015 to August 2025.

Prior to that, Mr. Wu held various positions in Xuzhou Biochemical Pharmaceutical Factory* (徐州生物化學製藥廠), Xuzhou (Wanbang) Biopharmaceuticals Manufactures Plant* (徐州(萬邦)生物化學製藥廠), Xuzhou Wanbang Biochemical Pharmaceutical Co., Ltd.* (徐州萬邦生化製藥有限公司) and Jiangsu Wanbang Biopharmaceutical Co., Ltd.* (江蘇萬邦生化醫藥股份有限公司) (which were predecessors of JiangsuWanbang Biopharmaceutical Company Limited* (江蘇萬邦生化醫藥集團有限責任公司)). Mr. Wu obtained an executive master of business administration (EMBA) from Saint Joseph's University in the United States in 2005.

Mr. Wu has entered into a service contract as an executive Director with the Company for a term of three years from 10 October 2025, subject to (i) retirement from office and re-election at the first annual general meeting of the Company after his appointment and (ii) retirement by rotation and re-election at least once every three years, in accordance with the articles of association of the Company and the corporate governance code set out in Appendix C1 to the Listing Rules. According to the terms of Mr. Wu's appointment, Mr. Wu will not receive any director's fee in his capacity as an executive Director but is entitled to the reimbursement of all reasonable out-of-pocket expenses incurred in the performance of his duties in connection with the business of the Company.

As at the Latest Practicable Date, Mr. Wu has (i) personal interest in 372,500 Shares; (ii) share options with respect to 1,237,374 Shares pursuant to the Post-IPO Share Option Scheme and (iii) performance share awards with respect to 530,303 Shares pursuant to the Pre-IPO ESOP, which, in aggregate represent approximately 0.60% of the total issued share capital of the Company within the meaning of Part XV of the SFO. Save as disclosed above, Mr. Wu does not have any other interests in the Shares, underlying Shares and debentures of the Company and its associated corporations within the meaning of Part XV of the SFO.

Save as disclosed above, Mr. Wu has confirmed that he does not (i) hold any other position in the Company or its subsidiaries; (ii) hold any directorship in any other public companies with securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) have any other major appointments and professional qualifications; (iv) have any relationship with any other Directors, senior management or substantial shareholder or controlling shareholders of the Company; or (v) have any other information which is discloseable nor has he been involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and the Company is not aware of any other matters concerning Mr. Wu's standing for re-election as Director that need to be brought to the attention of the Shareholders.

(2) **Mr. Wei Fu (傅唯)**, aged 43, was re-designated as a non-executive Director and honorary chairman of the Board on 10 October 2025. Mr. Fu was appointed as our Director in July 2017 and was previously re-designated as an executive Director in July 2020.

Mr. Fu has served as the chief executive officer and managing director of CBC Group, a healthcare dedicated private equity firm, since April 2014. From August 2011 to December 2013, Mr. Fu served as the general manager of the investment department at a wholly-owned subsidiary of Far East Horizon Limited, a financial services organization listed on the Stock Exchange (HKEX: 3360). From March 2008 to April 2010, Mr. Fu worked as an associate director at Standard Chartered Business Consulting (Beijing) Co., Ltd., where he was mainly responsible for private equity investments in infrastructure projects. From July 2006 to March 2008, Mr. Fu worked at Macquarie Capital (Singapore) Pte. Limited, where his last position was as a business analyst. Mr. Fu has been a director of I-Mab (NASDAQ: IMAB) since June 2018.

Mr. Fu received his bachelor's degree in electrical and electronic engineering from Nanyang Technological University in Singapore in February 2005.

Mr. Fu has entered into a service agreement with the Company on 22 September 2020. The term of appointment shall be for an initial term of three years from the Listing Date (subject to retirement as and when required under the Articles of Association), which will be automatically renewed for successive periods of three years until terminated in accordance with the terms of the service agreement. Mr. Fu is not entitled to receive any remuneration in his capacity as a non-executive Director and Mr. Fu is entitled to the

reimbursement of all reasonable out-of-pocket expenses incurred in relation to the discharge of his duties in connection with the business of the Company under his service agreement.

As at the Latest Practicable Date, Mr. Fu has in his capacity as founder of a discretionary trust, deemed interests in 87,342,927 Shares held by controlled corporations, C-Bridge Investment Everest Limited (40,468,000 Shares), C-Bridge IV Investment Two Limited (22,732,260 Shares), Everest Management Holding Co., Ltd. (21,683,167 Shares) and other corporations (2,459,500 Shares in total), which, in aggregate, represent approximately 24.7% of the total issued share capital of the Company within the meaning of Part XV of the SFO. Save as disclosed above, Mr. Fu does not have any other interests in the Shares, underlying Shares and debentures of the Company and its associated corporations within the meaning of Part XV of the SFO.

Save as disclosed above, Mr. Fu has confirmed that he does not (i) hold any other position in the Company or its subsidiaries; (ii) hold any directorship in any other public companies with securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) have any other major appointments and professional qualifications; (iv) have any relationship with any other Directors, senior management or substantial shareholder or controlling shareholders of the Company; or (v) have any other information which is discloseable nor has he been involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and the Company is not aware of any other matters concerning Mr. Fu's standing for re-election as Director that need to be brought to the attention of the Shareholders.

(3) **Mr. William Ki Chul Cho (曹基哲)**, aged 48, was appointed as a non-executive Director on 12 January 2024. He is currently a Senior Managing Director of CBC Group where he is a member of the Management Committee and helps lead the portfolio management and private equity investments functions of CBC Group.

Prior to joining CBC Group in 2023, he was the Chief Financial Officer of Zai Lab Limited (stock code: 9688.hk) from March 2018 to July 2023. Mr. Cho also served as Managing Director and Head of Asia Healthcare Investment Banking at Citigroup from 2011 to 2018. Based in Hong Kong since 2011, Mr. Cho was responsible for healthcare client coverage at Citigroup across the Asia Pacific region and led many biopharma transactions in China. Prior to this, he was based in the United States, involved in healthcare investment banking and also spent time in corporate development for a pharmaceutical services company. Mr. Cho started his career at Ernst & Young LLP as an auditor in the healthcare group. Mr. Cho was appointed as a non-executive director of Hugel Inc. (KOSDAQ: 145020) on 29 March 2024.

Mr. Cho obtained his MBA degree from the Wharton School of the University of Pennsylvania, his Master degree in Accounting from the University of Virginia, and his Bachelor's degree in Business Administration from the University of Southern California's Marshall School of Business.

Mr. Cho has entered into a service agreement with the Company on 12 January 2024. The term of appointment shall be for an initial term of three years (subject to retirement as and when required under the Articles of Association), which will be automatically renewed for successive periods of three years until terminated in accordance with the terms of the service agreement. Mr. Cho is not entitled to receive any remuneration in his capacity as a non-executive Director and Mr. Cho is entitled to the reimbursement of all reasonable out-of-pocket expenses incurred in relation to the discharge of his duties in connection with the business of the Company under his service agreement.

Save as disclosed above, Mr. Cho has confirmed that he does not (i) hold any other position in the Company or its subsidiaries; (ii) hold any directorship in any other public companies with securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) have any other major appointments and professional qualifications; (iv) have any relationship with any other Directors, senior management or substantial shareholder or controlling shareholder of the Company; (v) have any interest in the Shares, underlying Shares and debentures of the Company and its associated corporations within the meaning of Part XV of the SFO; or (vi) have any other information which is discloseable nor has he been involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and the Company is not aware of any other matters concerning Mr. Cho's standing for re-election as Director that need to be brought to the attention of the Shareholders.

(4) **Mr. Xin Sun (孫欣)**, aged 45, was appointed as a non-executive director on 11 December 2025, is currently a managing director and co-head of Private Equity Investment at CBC Group, a substantial shareholder of the Company. He has over 20 years of experience in private equity, investment banking and the healthcare industry. Prior to joining CBC Group, Mr. Sun was most recently a managing director at Hillhouse Investment, a global investment management firm based in Asia. He was a key member of the healthcare private equity team since 2017, where he led over 30 investments and deployed over USD3 billion of investments across various stages from growth equity to leveraged buyout. He covered multiple sub-sectors including pharmaceuticals/biotech, medical devices and healthcare services. Prior to joining Hillhouse, he was a vice president at Affinity Equity Partners, an Asia-focused private equity fund based in Hong Kong. Prior to that, he worked in the investment banking division of Goldman Sachs in New York, with a focus on healthcare M&A and financing. He started his career in the pharmaceuticals/biotech industry as a research scientist at Boehringer Ingelheim and Genentech, respectively. Mr. Sun was the non-executive director of Luye Pharma Group Limited (stock code: 2186) from 8 February 2021 to 6 December 2023 and Shanghai MicroPort MedBot (Group) Co., Ltd. (stock code: 2252) from 17 September 2020 to 29 December 2023 respectively.

Mr. Sun received his MBA from Columbia Business School, his master's degree in Molecular Genetics from Duke University and bachelor's degree in Biological Sciences from Peking University.

Mr. Sun has entered into an appointment letter with the Company for a term of three years from 11 December 2025, subject to (i) retirement from office and re-election at the first annual general meeting of the Company after his appointment and (ii) retirement by rotation and re-election at least once every three years, in accordance with the articles of association of the Company and the corporate governance code set out in Appendix C1 to the Listing Rules. According to the terms of Mr. Sun's appointment, Mr. Sun will not receive any remuneration or benefits in his capacity as a non-executive Director but is entitled to the reimbursement of all reasonable out-of-pocket expenses incurred in the performance of his duties in connection with the business of the Company.

Save as disclosed above, Mr. Sun has confirmed that he does not (i) hold any other position in the Company or its subsidiaries; (ii) hold any directorship in any other public companies with securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) have any other major appointments and professional qualifications; (iv) have any relationship with any other Directors, senior management or substantial shareholder or controlling shareholder of the Company; (v) have any interest in the Shares, underlying Shares and debentures of the Company and its associated corporations within the meaning of Part XV of the SFO; or (vi) have any other information which is discloseable nor has he been involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and the Company is not aware of any other matters concerning Mr. Sun's standing for re-election as Director that need to be brought to the attention of the Shareholders.

(5) Ms. Hoi Yam Chui (徐海音), (alias: **徐海瑛)** (former name: **徐海英)**, aged 59, was appointed as an independent non-executive Director, chairperson of the Remuneration Committee and member of the Audit Committee and Nomination Committee on 19 January 2023.

Ms. Chui was appointed as an independent non-executive director of Abbisko Cayman Limited (和譽開曼有限責任公司), a company listed on the Stock Exchange (HKEX: 2256), on 28 February 2025. Ms. Chui has served as an independent non-executive director of TransThera Sciences (Nanjing), Inc. (藥捷安康(南京)科技股份有限公司), a company listed on the Stock Exchange (HKEX: 2617), since October 2022. TransThera Sciences (Nanjing), Inc. was listed on the Stock Exchange on 23 June 2025.

Previously, Ms. Chui was also an executive director of China Biotech Services Holdings Limited (中國生物科技服務控股有限公司), a company listed on the GEM of the Stock Exchange (stock code: 8037), from December 2022 to June 2023 and redesignated as a non-executive director from 30 June 2023 to 13 June 2024. She was president of Harbin Pharmaceutical Group Co., Ltd. (哈藥集團股份有限公司) ("**Harbin Pharmaceutical**"), a company listed on the Shanghai Stock Exchange (stock code: 600664), from March 2019 to May 2022 and a director of Harbin Pharmaceutical from January 2021 to May 2022, where she was responsible for the overall business operation. Ms. Chui has previously also worked in China Hewlett-Packard Co., Ltd. and Novartis International. Ms. Chui

received her bachelor's degree in Economic Administration and master's degree in Finance from Peking University, the People's Republic of China in July 1990 and July 2001, respectively.

Ms. Chui has entered into an appointment letter with the Company for a term of three years commencing from 19 January 2026 or until the third annual general meeting of the Company since the date of her appointment date, whichever is sooner (subject to retirement as and when required under the Articles of Association). Either party may terminate the agreement by giving not less than three months' written notice. According to the terms of Ms. Chui's appointment, Ms. Chui is entitled to a director's fee of US$50,000 per annum which is determined by reference to her duties and responsibilities in the Company and the prevailing market conditions and Ms. Chui is entitled to the reimbursement of all reasonable out-of-pocket expenses incurred in relation to the discharge of her duties in connection with the business of the Company.

Save as disclosed above, Ms. Chui has confirmed that she does not (i) hold any other position in the Company or its subsidiaries; (ii) hold any directorship in any other public companies with securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) have any other major appointments and professional qualifications; (iv) have any relationship with any other Directors, senior management or substantial shareholder or controlling shareholder of the Company; (v) have any interest in the Shares, underlying Shares and debentures of the Company and its associated corporations within the meaning of Part XV of the SFO; or (vi) have any other information which is discloseable nor has she been involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and the Company is not aware of any other matters concerning Ms. Chui's standing for re-election as Director that need to be brought to the attention of the Shareholders.

The following is an explanatory statement required by the Listing Rules to provide the Shareholders with requisite information reasonably necessary for them to make an informed decision on whether to vote for or against the ordinary resolution to be proposed at the AGM in relation to the granting of the Repurchase Mandate.

1. SHARE CAPITAL

As at the Latest Practicable Date, the issued share capital of the Company comprised 353,799,975 Shares (with no treasury Shares).

Subject to the passing of the ordinary resolution set out in item 4 of the notice of the AGM in respect of the granting of the Repurchase Mandate and on the basis that no further Shares are issued or repurchased before the AGM, i.e. being 353,799,975 Shares, the Directors would be authorized under the Repurchase Mandate to repurchase, during the period in which the Repurchase Mandate remains in force, a total of 35,379,997 Shares, representing 10% of the total number of Shares in issue as at the date of the Annual General Meeting.

2. REASONS FOR SHARE REPURCHASE

The Directors believe that the granting of the Repurchase Mandate is in the best interests of the Company and the Shareholders.

Shares repurchase may, depending on the market conditions and funding arrangements at the time, lead to an enhancement of the net asset value per Share and/or earnings per Share and will only be made when the Directors believe that such a repurchase will benefit the Company and the Shareholders.

3. FUNDING OF SHARE REPURCHASE

The Company may only apply funds legally available for share repurchase in accordance with its Articles of Association, the laws of Cayman Islands and/or any other applicable laws, as the case may be.

4. IMPACT OF SHARE REPURCHASE

There might be a material adverse impact on the working capital or gearing position of the Company (as compared with the position disclosed in the audited accounts contained in the annual report of the Company for the year ended 31 December 2025) in the event that the Repurchase Mandate was to be carried out in full at any time during the proposed repurchase period. However, the Directors do not intend to exercise the Repurchase Mandate to such extent as would, in the circumstances, have a material adverse effect on the working capital requirements of the Company or the gearing levels which in the opinion of the Directors are from time to time appropriate for the Company.

5. MARKET PRICES OF SHARES

The highest and lowest prices per Share at which Shares have traded on the Stock Exchange in each of the previous twelve months immediately prior to the Latest Practicable Date were as follows:

Month	Highest *HK$*	Lowest *HK$*
2025		
May	51.15	41.40
June	63.75	41.55
July	77.55	62.65
August	75.15	61.50
September	66.35	54.25
October	58.60	47.50
November	51.20	42.72
December	50.30	36.70
2026		
January	43.30	36.84
February	41.80	35.54
March	39.18	31.70
April	42.00	34.48
May *(up to the Latest Practicable Date)*	35.10	28.50

6. GENERAL

To the best of their knowledge and having made all reasonable enquiries, none of the Directors nor any of their respective close associates (as defined in the Listing Rules) have any present intention to sell any Shares to the Company in the event that the granting of the Repurchase Mandate is approved by the Shareholders.

The Company has not been notified by any core connected persons (as defined in the Listing Rules) of the Company that they have a present intention to sell any Shares to the Company, or that they have undertaken not to sell any Shares held by them to the Company in the event that the granting of the Repurchase Mandate is approved by the Shareholders.

The Directors will exercise the power of the Company to repurchase Shares pursuant to the Repurchase Mandate in accordance with the Listing Rules, the applicable laws of Cayman Islands, and the Memorandum and Articles of Association.

The Company may cancel such repurchased Shares or hold them as treasury Shares, subject to market conditions and the Group's capital management needs at the relevant time of the repurchases.

For any treasury Shares deposited with CCASS pending resale on the Stock Exchange, the Company shall (i) procure its broker not to give any instructions to HKSCC to vote at general meetings of the Company for the treasury Shares deposited with CCASS; and (ii) in the case of dividends or distributions, withdraw the treasury Shares from CCASS, and either re-register them in its own name as treasury Shares or cancel them, in each case before the record date for the dividends or distributions, or take any other measures to ensure that it will not exercise any shareholders' rights or receive any entitlements which would otherwise be suspended under the applicable laws if those Shares were registered in its own name as treasury Shares.

The Company has confirmed that neither the explanatory statement nor the Repurchase Mandate has any unusual features.

7. TAKEOVERS CODE

If as a result of a repurchase of Shares pursuant to the Repurchase Mandate, a Shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition of voting rights for the purposes of the Takeovers Code. Accordingly, a Shareholder or a group of Shareholders acting in concert (within the meaning under the Takeovers Code), depending on the level of increase in the Shareholder's interest, could obtain or consolidate control of the Company and thereby become obliged to make a mandatory offer in accordance with Rule 26 of the Takeovers Code.

As of the Latest Practicable Date, to the best knowledge of the Company, Mr. Wei Fu and CBC Group were deemed to control approximately 24.7% of the total number of issued Shares. Assuming there will be no change in the number of issued Shares or the shareholding of Mr. Wei Fu and CBC Group, and if the Repurchase Mandate is exercised in full, the shareholding of Mr. Wei Fu and CBC Group would be increased to approximately 27.4%. Thus, it will not give rise to an obligation by Mr. Wei Fu or CBC Group to make a mandatory offer under Rule 26 of the Takeovers Code.

The Directors do not propose to exercise the Share Repurchase Mandate to such an extent as would, in the circumstances, give rise to an obligation to make a mandatory offer in accordance with Rule 26 of the Takeovers Code and/or result in the aggregate number of Shares held by the public shareholders falling below the prescribed minimum percentage required by the Stock Exchange.

8. SHARE REPURCHASE MADE BY THE COMPANY

During the 6 months prior to the Latest Practicable Date, the Company had not repurchased any of the Shares (whether on the Stock Exchange or otherwise).

EVEREST MEDICINES
云 顶 新 耀

Everest Medicines Limited

雲頂新耀有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1952)

NOTICE OF ANNUAL GENERAL MEETING

The annual general meeting will be held by way of virtual meeting via the Online Platform which can be accessed from any location with connection to the internet. Shareholders of the Company need not to attend the annual general meeting in person.

NOTICE IS HEREBY GIVEN that the annual general meeting ((the "**AGM**" or "**Annual General Meeting**") of Everest Medicines Limited (the "**Company**") will be held at on Friday, 26 June 2026 at 9:30 a.m. by way of virtual meeting via the Online Platform for the following purposes:

1. To receive and adopt the audited consolidated financial statements of the Company for the year ended 31 December 2025 and the reports of the directors of the Company (the "**Directors**") and the independent auditor of the Company (the "**Auditor**") thereon.

2(a). To re-elect Mr. Yifang Wu as an executive Director;

2(b). To re-elect Mr. Wei Fu as a non-executive Director;

2(c). To re-elect Mr. William Ki Chul Cho as a non-executive Director;

2(d). To re-elect Mr. Xin Sun as a non-executive Director;

2(e). To re-elect Ms. Hoi Yam Chui as an independent non-executive Director;

2(f). To authorize the board of Directors (the "**Board**") to fix the remuneration of the Directors of the Company.

3. To re-appoint Ernst & Young as the Auditor to hold office until the conclusion of the next annual general meeting of the Company and to authorize the Board to fix their remuneration.

4. To consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:

"**THAT**:

(a) subject to compliance with the prevailing requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and paragraph (b) below, a general mandate be and is hereby generally and unconditionally given to the Directors to exercise during the Relevant Period (as defined below) all the powers of the Company to repurchase its shares in accordance with all applicable laws, rules and regulations;

(b) the total number of shares of the Company to be repurchased pursuant to the mandate in paragraph (a) above shall not exceed 10% of the total number of issued shares of the Company (excluding any shares that are held as treasury shares (which shall have the meaning ascribed to it under the Rules Governing the Listing of Securities on The Stock Exchange of the Hong Kong Limited)) as at the date of passing of this resolution (subject to adjustment in the case of any consolidation or subdivision of shares of the Company after the date of passing of this resolution); and

(c) for the purposes of this resolution:

"**Relevant Period**" means the period from the passing of this resolution until whichever is the earliest of:

(i) the conclusion of the next annual general meeting of the Company;

(ii) the expiration of the period within which the next annual general meeting of the Company is required by the memorandum and articles of association of the Company or any applicable laws to be held; and

(iii) the date on which the authority set out in this resolution is revoked or varied by an ordinary resolution of the shareholders in general meeting."

5. To consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:

"**THAT**:

(a) subject to compliance with the prevailing requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and paragraph (b) below, a general mandate be and is hereby generally and unconditionally given to the Directors to allot, issue and deal with additional shares (including any sale and transfer of shares out of treasury that are held as treasury shares) in the capital of the Company and to make or grant offers,

agreements and options which might require the exercise of such powers during or after the end of the Relevant Period (as defined below) in accordance with all applicable laws, rules and regulations;

(b) the aggregate number of shares allotted or agreed conditionally or unconditionally to be allotted by the Directors pursuant to the mandate in paragraph (a) above, otherwise than pursuant to:

(i) a Rights Issue (as defined below);

(ii) the exercise of options under a share option scheme of the Company; and

(iii) any scrip dividend scheme or similar arrangement providing for the allotment of shares in lieu of the whole or part of a dividend on shares of the Company in accordance with the memorandum and articles of association of the Company,

shall not exceed 20% of the total number of issued shares of the Company (excluding any shares that are held as treasury shares) as at the date of passing of this resolution (subject to adjustment in the case of any consolidation or subdivision of shares of the Company after the date of passing of this resolution); and

(c) for the purposes of this resolution:

"**Relevant Period**" means the period from the passing of this resolution until whichever is the earliest of:

(i) the conclusion of the next annual general meeting of the Company;

(ii) the expiration of the period within which the next annual general meeting of the Company is required by the memorandum and articles of association of the Company or any applicable laws to be held; and

(iii) the date on which the authority set out in this resolution is revoked or varied by an ordinary resolution of the shareholders in general meeting.

"**Rights Issue**" means an offer of shares open for a period fixed by the Directors to holders of shares of the Company or any class thereof on the register on a fixed record date in proportion to their then holdings of such shares or class thereof (subject to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements or having regard to any restrictions or obligations under the laws of any relevant jurisdiction or the requirements of any recognized regulatory body or any stock exchange)."

6. To consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:

"**THAT** conditional upon the passing of the resolutions set out in items 4 and 5 of the notice convening this meeting (the "**Notice**"), the general mandate referred to in the resolution set out in item 5 of the Notice be and is hereby extended by the addition to the aggregate number of shares which may be allotted and issued (including the sale and transfer of shares out of treasury that are held as treasury shares) or agreed conditionally or unconditionally to be allotted and issued (including the sale and transfer of shares out of treasury that are held as treasury shares) by the Directors pursuant to such general mandate of the number of shares repurchased by the Company pursuant to the mandate referred to in resolution set out in item 4 of the Notice, provided that such number of shares shall not exceed 10% of the total number of issued shares of the Company (excluding any treasury shares) as at the date of passing of this resolution (subject to adjustment in the case of any consolidation or subdivision of shares of the Company after the date of passing of this resolution)."

By Order of the Board
Everest Medicines Limited
Yifang Wu
Chairman and Executive Director

Hong Kong, 3 June 2026

Notes:

1. The AGM will be a virtual meeting. All shareholders of the Company (the "**Shareholders**") can attend, participate and vote at the AGM by accessing to the website at (https://meetings.computershare.com/everestmed_2026AGM) (the "**Online Platform**"). Shareholders are reminded that physical attendance in person at the AGM is NOT necessary. Shareholders joining the AGM using the Online Platform will be counted towards the quorum and they will be able to cast their votes and submit questions through the Online Platform.

2. Details regarding AGM arrangements and login access for joining the AGM through the Online Platform are provided on the notification letter to be despatched together with the Company's circular dated 3 June 2026 (the "**Circular**") and related documents. Shareholders attend the AGM are reminded to read the "GUIDANCE FOR THE AGM" set out in the Circular prior to joining the AGM.

3. All resolutions at the meeting will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). The results of the poll will be published on the websites of Hong Kong Exchanges and Clearing Limited and the Company in accordance with the Listing Rules.

4. Any shareholder of the Company entitled to attend and vote at the meeting is entitled to appoint any number of proxies to attend and vote instead of him. A proxy need not be a shareholder of the Company. If more than one proxy is appointed, the number of shares in respect of which each such proxy so appointed must be specified in the relevant form of proxy. Every shareholder present in person or by proxy shall be entitled to one vote for each share held by him.

5. In order to be valid, the form of proxy together with the power of attorney or other authority, if any, under which it is signed or a certified copy of that power of attorney or authority, must be deposited at the Company's Hong Kong Share Registrar, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not less than 48 hours before the time appointed for the meeting or the adjourned meeting (as the case may be). Completion and return of the form of proxy shall not preclude a shareholder of the Company from attending and voting in person at the meeting and, in such event, the instrument appointing a proxy shall be deemed to be revoked.

6. For determining the entitlement to attend and vote at the meeting, the Register of Members of the Company will be closed from Tuesday, 23 June 2026 to Friday 26 June 2026, both dates inclusive, during which period no transfer of shares will be registered. In order to be eligible to attend and vote at the Annual General Meeting, unregistered holders of shares of the Company shall ensure that all transfer documents accompanied by the relevant share certificates must be lodged with the Company's Hong Kong Share Registrar, Computershare Hong Kong Investor Services Limited at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong for registration not later than 4:30 p.m. on Monday, 22 June 2026.

7. Shareholders attending the AGM will be able to raise questions relevant to the proposed resolutions during the AGM using the Online Platform. Prior to the AGM, Shareholders are also welcome to send such questions or matters in writing to the Company's email at ir@everestmedicines.com no later than 6:00 p.m. on Wednesday, 24 June 2026. The Company will endeavor to address relevant questions in relation to the proposed resolutions at the AGM. However, the Company may not be able to answer all the questions during the time allocated. Unanswered questions may be responded to after the AGM.

8. Treasury shares, if any and registered under the name of the Company, shall have no voting rights at the Annual General Meeting. For the avoidance of doubt and for the purpose of the Listing Rules, holders of treasury shares of the Company (if any) are not entitled to vote at the Annual General Meeting.

9. As at the date of this notice, the Board comprises Mr. Yifang Wu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. Wei Fu, Mr. William Ki Chul Cho and Mr. Xin Sun as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.

If Shareholders have any questions relating to the AGM, please contact the share registrar of the Company as follows:

Computershare Hong Kong Investor Services Limited
17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong
Tel: (852) 2862 8555
Fax: (852) 2865 0990
Online Enquiries: www.computershare.com/hk/en/online_feedback